2021
Miglustat Therapy for SCARB2-Associated Action Myoclonus–Renal Failure Syndrome
Quraishi IH, Szekely AM, Shirali AC, Mistry PK, Hirsch LJ. Miglustat Therapy for SCARB2-Associated Action Myoclonus–Renal Failure Syndrome. Neurology Genetics 2021, 7: e614. PMID: 34337151, PMCID: PMC8320328, DOI: 10.1212/nxg.0000000000000614.Peer-Reviewed Original ResearchAction myoclonus-renal failure syndromeNeurologic symptomsAction myoclonusFailure syndromeProgressive myoclonic epilepsySubstrate reduction therapyWhole-exome sequencingMiglustat therapyAvailable medicationsEarly mortalityReduction therapyMyoclonic epilepsySteady worseningGaucher diseaseMyoclonusGlycosphingolipid metabolismExome sequencingGene mutationsGlucosylceramide accumulationPatientsSeizuresMiglustatSyndromeTherapySymptoms
2013
Primary dystonias and genetic disorders with dystonia as clinical feature of the disease
Moghimi N, Jabbari B, Szekely AM. Primary dystonias and genetic disorders with dystonia as clinical feature of the disease. European Journal Of Paediatric Neurology 2013, 18: 79-105. PMID: 23911094, DOI: 10.1016/j.ejpn.2013.05.015.Peer-Reviewed Original ResearchConceptsPrimary dystoniaClinical featuresSustained muscle contractionsCharacteristic clinical featuresClinical entityAbnormal postureMovement disordersDystoniaClinical practiceClinical phenomenologyAdvances of geneticsGenetic syndromesMuscle contractionRepetitive movementsUnderlining etiologiesDisordersCommon formMonogenic disordersGenetic disordersMolecular underpinningsDetailed searchMendelian disordersComplex casesLarge groupSyndrome